Senate does not negotiate with Baucus
Executive Summary
Medicare direct drug price negotiation bill stalls in the Senate April 18, as Sen. Max Baucus, D-Mont., fails to win enough votes for "cloture," which would bring the Senate to a vote. As passed by the Finance Committee, Baucus' S 3 would permit HHS to negotiate Part D prices with drug manufacturers and add provisions in other areas such as comparative effectiveness research and data sharing with congressional agencies (1"The Pink Sheet" April 16, 2007, p. 4)...
You may also be interested in...
Comparative Effectiveness Bill Calls For Private Group To Plan Research
While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings
Medicare Part D Boosts Public Share Of Retail Drug Spending To 34 Percent
The public sector picked up 34 percent of the tab for prescription drugs purchased at retail in 2006, up from 28 percent the year before, with Medicare Part D underlying much of that shift, according to a report by CMS economists
OIG Is Scrutinizing Whether Part D Discounts Are Passed On To Enrollees
The issue of whether Medicare drug plan enrollees see pocketbook savings as a result of Part D drug price concessions is under HHS Office of Inspector General evaluation in a series of ongoing reviews slated for completion in 2008 as well as a newly initiated study